Skip to main content

Table 1 Effect of different types of stem cells on biochemical measurements (n = 20 and n = 5 for day subgroups, mean ± SD)

From: Comparative study of allogenic and xenogeneic mesenchymal stem cells on cisplatin-induced acute kidney injury in Sprague-Dawley rats

 

Group I

Group II

Group III

Group IV

Group V

Group VI

negative control

cisplatin ‘CDDP’-treated

cisplatin + rBMSCs-treated

cisplatin + hADSCs-treated

cisplatin + hAFSCs-treated

cisplatin + DMEM culture media-treated

Sr. Cr. (mg/dL)

 Day 4

0.40 ± 0.12

1.92 ± 0.03a

0.92 ± 0.05ab

0.97 ± 0.02ab

1.02 ± 0.08ab

1.88 ± 0.10acde

 Day 7

0.37 ± 0.12

1.61 ± 0.05a

0.79 ± 0.04ab

0.87 ± 0.06ab

0.85 ± 0.07ab

1.63 ± 0.03acde

 Day 11

0.40 ± 0.11

1.00 ± 0.07a

0.67 ± 0.1ab

0.72 ± 0.05ab

0.70 ± 0.06ab

1.02 ± 0.10acde

 Day 30

0.39 ± 0.10

0.77 ± 0.03 a

0.52 ± 0.06ab

0.58 ± 0.06ab

0.58 ± 0.05ab

0.81 ± 0.04acde

BUN (mg/dL)

 Day 4

18.6 ± 1.14

85.6 ± 1.67a

32.0 ± 1.58ab

30.2 ± 0.83ab

34.4 ± 1.14ab

85.4 ± 1.14acde

 Day 7

18.2 ± 1.48

55.2 ± 1.30a

27.2 ± 1.30ab

27.8 ± 1.30ab

28.0 ± 1.22ab

53.8 ± 0.84acde

 Day 11

17.2 ± 1.48

32.3 ± 1.48a

24.2 ± 0.83ab

24.2 ± 1.30ab

24.4 ± 0.89ab

32.4 ± 1.51acde

 Day 30

18.0 ± 1.58

26.4 ± 0.55a

22.2 ± 0.83ab

22.4 ± 0.89ab

23.2 ± 0.84ab

26.2 ± 0.83acde

Cr. Cl. (mL/min/100 gm)

 Day 4

1.62 ± 0.44

0.007 ± 0.001a

0.021 ± 0.005a

0.021 ± 0.006a

0.018 ± 0.006a

0.008 ± 0.001a

 Day 7

1.78 ± 0.55

0.014 ± 0.001a

0.052 ± 0.008a

0.048 ± 0.001a

0.045 ± 0.001a

0.012 ± 0.002a

 Day 11

1.86 ± 0.56

0.05 ± 0.01a

0.07 ± 0.01a

0.06 ± 0.01a

0.06 ± 0.007a

0.05 ± 0.013a

 Day 30

1.76 ± 0.55

0.36 ± 0.17a

0.92 ± 0.23a

0.89 ± 0.15a

1.00 ± 0.14ab

0.46 ± 0.26a

  1. Values are expressed as mean ± SD. A significant difference (P < 0.05) between different groups was done by Bonferroni post hoc for multiple comparisons
  2. rBMSCs rat bone marrow stem cells, hADSCs human adipose tissue-derived stem cells, hAFSCs human amniotic fluid-derived stem cells, DMEM Dulbecco’s modified Eagle’s medium, Sr. Cr. serum creatinine, BUN blood urea nitrogen, Cr. Cl. creatinine clearance
  3. aSignificant difference vs. negative control group bSignificant difference vs. cisplatin-treated group cSignificant difference vs. cisplatin + rBMSCs-treated group dSignificant difference vs. cisplatin + hADSCs-treated group eSignificant difference vs. cisplatin + hAFSCs-treated group